Kaiser Permanente北加州引入人乳头瘤病毒与细胞学联合筛查后宫颈癌前病变及癌症诊断的日历周期趋势
研究基于Kaiser Permanente北加州2003年引入人乳头瘤病毒(HPV)与细胞学联合筛查的数据,分析2003-2018年每1000名筛查者中宫颈癌前病变(CIN3和AIS)及癌症(SCC和ADC)诊断的日历趋势。结果显示CIN3和AIS诊断分别每年增加约2%和3%,SCC诊断每年下降5%,ADC诊断无变化。SCC:ADC比值从2003-2006年的约2.5:1降至2015-2018年的1.3:1,而CIN3:AIS比值相对稳定在约10:1。
要点
- CIN3和AIS诊断分别每年增加约2%和3%(趋势P值均<0.001)。
- SCC诊断每年下降5%(趋势P值<0.001),ADC诊断无变化。
- SCC:ADC比值从约2.5:1降至1.3:1,CIN3:AIS比值相对稳定在约10:1。
核心结论
- 自KPNC引入联合筛查以来,CIN3检出随时间增加,可能随后导致SCC减少,但未观察到ADC下降。
- ADC缺乏效果的一种可能解释是AIS诊断不足。
- 需要开发并临床验证识别和治疗ADC高风险女性的新策略。
研究设计与样本
- 基于Kaiser Permanente北加州的数据,2003年对≥30岁女性引入每三年一次的HPV与细胞学联合筛查。
- 分析2003-2018年每1000名筛查者中宫颈癌前病变(CIN3和AIS)及癌症(SCC和ADC)诊断的日历趋势。
- 计算鳞状与腺性诊断比值(SCC:ADC和CIN3:AIS)。
主要发现
- CIN3诊断每年增加约2%(趋势P值<0.001),AIS诊断每年增加约3%(趋势P值<0.001)。
- SCC诊断每年下降5%(趋势P值<0.001),ADC诊断无变化。
- 上述模式在各年龄组(30-39、40-49、50-64岁)中普遍观察到。
- 即使在2003-2006年开始联合筛查的女性中,每1000名筛查者的ADC诊断也无变化。
- SCC:ADC从2003-2006年的约2.5:1降至2015-2018年的1.3:1,CIN3:AIS相对稳定在约10:1。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The longer-term impact of introducing human papillomavirus (HPV) testing into routine cervical cancer screening on precancer and cancer rates by histologic type has not been well described. Calendar trends in diagnoses were examined using data from Kaiser Permanente Northern California, which introduced triennial HPV and cytology co-testing in 2003 for women aged ≥30 years. METHODS: We examined trends in cervical precancer (cervical intraepithelial neoplasia grade 3 [CIN3] and adenocarcinoma in situ [AIS]) and cancer (squamous cell carcinoma [SCC] and adenocarcinoma [ADC]) diagnoses per 1000 screened during 2003-2018. We examined ratios of squamous vs. glandular diagnoses (SCC:ADC and CIN3:AIS). RESULTS: CIN3 and AIS diagnoses increased approximately 2% and 3% annually, respectively (ptrend < 0.001 for both). While SCC diagnoses decreased by 5% per annually (ptrend < 0.001), ADC diagnoses did not change. These patterns were generally observed within each age group (30-39, 40-49, and 50-64 years). ADC diagnoses per 1000 screened did not change even among those who underwent co-testing starting in 2003-2006. SCC:ADC decreased from approximately 2.5:1 in 2003-2006 to 1.3:1 in 2015-2018 while the CIN3:AIS remained relatively constant, ∼10:1. CONCLUSIONS: Since its introduction at KPNC, co-testing increased the detection of CIN3 over time, which likely caused a subsequent reduction of SCC. However, there has been no observed decrease in ADC. One possible explanation for lack of effectiveness against ADC is the underdiagnosis of AIS. Novel strategies to identify and treat women at high risk of ADC need to be developed and clinically validated.
引用
- Befano B, Wentzensen N, Lorey T, et al. Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California. Gynecol Oncol. 2024. PMID: 38301311. doi:10.1016/j.ygyno.2024.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。